title: Improvement in quality of life for cancer patients treated with epoetin alfa.
abstract: Anaemia is a common complication of cancer and cancer therapies, and fatigue is one of the most common symptoms of anaemia, disrupting functional performance and reducing overall quality of life. The positive effects of treating renal patients with recombinant human erythropoietin are well documented. This case report series details the specific effects of fatigue on individual patients with cancer and their way of life, and describes their significant improvement in lifestyle following the reversal of anaemia using recombinant human erythropoietin, epoetin alfa.
authors.affiliation: Janssen-Cilag Ltd, High Wycombe, Buckinghamshire, UK. slibrett@jacgb.jnj.com
authors.forename: S E
authors.initials: SE
authors.lastname: Libretto
authors.forename: P J
authors.initials: PJ
authors.lastname: Barrett-Lee
authors.forename: K
authors.initials: K
authors.lastname: Branson
authors.forename: D W
authors.initials: DW
authors.lastname: Gorst
authors.forename: R
authors.initials: R
authors.lastname: Kaczmarski
authors.forename: K
authors.initials: K
authors.lastname: McAdam
authors.forename: P
authors.initials: P
authors.lastname: Stevenson
authors.forename: R
authors.initials: R
authors.lastname: Thomas
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D011788:Quality of Life; D011994:Recombinant Proteins
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa